Syndrome antiphospholipide catastrophique (CAPS / Syndrome ya Asherson): Tempête ya thrombose microvasculaire multi-organique na kati ya poso moko mpe thérapie triple na Plasmaphérèse¶

Syndrome antiphospholipide ya likama (CAPS, oyo eyebani mpe na nkombo yango Asherson's Syndrome nsima ya monganga Ronald Asherson, oyo alobelaki yango mpo na mbala ya liboso na 1992) ezali lolenge ya Syndrome antiphospholipide (APS), kobeta moke koleka 1 percent ya bato ya maladi ya APS (with nearly 50 percent of cases occurring as the very first clinical presentation in a patient who never knew they had APS). Nzokande APS classique mbala mingi esalaka ete misisa moko ya minene ekangama ya misisa to ya misisa ya makila (such as a single deep vein thrombosis, pulmonary embolism, or stroke) to kobungisa zemi mbala na mbala, CAPS ezali "mopepe ya thrombotique" oyo epanzani, oyo ebakisami na complément (Thrombotic Microangiopathy [TMA] + syndrome ya réponse inflammatoire systémique [SIRS]) oyo ekangamaka na mbala moko ba microvessels ya mike ya ba systèmes organes misato to koleka na moins de 7 jours, mingi mingi rein (73%: hypertension maligne, proteinurie, mpe insuffisance rénale aiguë), poumons (60%: ARDS, embolie pulmonaire, mpe hémorragie alvéolaire diffuse), bongo (56%: AVC, ba crises, thrombose veineuse cérébrale, mpe encéphalopathie), motema (50%: micro-infarctus myocardique na ba végétations ya valve ya Libman-Sacks), loposo (47%: livedo racémosa, ischémie numérique ya mpasi, mpe nécrose cutanée), mpe glandes surrénales (bilateral adrenal hemorrhage/infarction causing refractory hypotensive shock). Po CAPS etambwisami na mécanisme "Two-Hit", esika ba anticorps antiphospholipides ya titre ya likolo oyo ezalaki liboso (Lupus Anticoagulant [LA], . Anti-Cardiolipin [aCL] IgG/IgM, mpe Anti-Beta-2-Glycoprotein-I [aB2GPI] IgG/IgM) ezali kopela na déclencheur aigu "Second Hit" (bacterial or viral infection in 49%, surgical procedures or trauma in 17%, abrupt withdrawal or subtherapeutic INR of Warfarin, malignancy, pregnancy/puerperium, or oral contraceptive estrogen), kozongisa nsima lisalisi ya monganga ememaka ** .80 to 90 percent taux ya liwa**, nzokande bobandi ya mbala moko na ICU ya CAPS "Triple Thérapie" ekataka liwa na katikati. Soki mobɛli oyo azali na Lupus oyo eyebani (SLE), Syndrome antiphospholipide, to thrombocytopénie oyo ekoki kolimbolama te ebimisaka bilembo ya mbalakaka ya binama mingi (shortness of breath, confusion, chest or flank pain, mottled purple skin, or dark/absent urine), benga esika ofandi banimero ya mbalakaka mbala moko. Tala mpe ba guides na biso ya moninga na crise surrénale mpe injection ya urgence ya maladie ya Addison, . ba crises ya eclampsie, syndrome ya HELLP, mpe prééclampsie sima ya kobota, mpe sepsis mpe choc septique.

Departema na yo ya urgence ya mbala moko mpe priorité ya ICU ezali ya ko lancer "Thérapie Triple CAPS" empirique mobimba mbala moko na soupçon clinique ya liboso mpenza ya thrombose microvasculaire multi-organes (WITHOUT waiting days for confirmatory antiphospholipid antibody titers or tissue biopsy): (1) Héparine non fractionnée intraveineuse thérapeutique (UFH) ( ) .not only to halt fibrin clot propagation, but because heparin directly inhibits complement activation [C3/C5 convertase]), (2) Ba corticostéroïdes oyo epesamaka na misisa ya dose makasi (Methylprednisolone 500 to 1,000 mg/day IV for 3 days, followed by 1 to 2 mg/kg/day) ( ) .to extinguish the NF-kappa-B endothelial cytokine storm), mpe (3) Echange ya plasma thérapeutique ya mbala moko mokolo na mokolo (Plasmapheresis / TPE kobongola volime ya plasma 1,0 kino 1,5 na Plasma/Albumine Congelé ya sika) MPE/TO Immunoglobuline Intraveineuse ya Dose makasi (IVIG, . 0.4 g/kg/day IV for 5 days), tango bazali ko traité déclencheur infectieux sous-jacent na ba antibiotiques ya spectre large mpe ko déployer inhibiteur ya complément terminal anti-C5 Eculizumab (Soliris) to anti-CD20 Rituximab mpo na ba cas réfractaires.

Sala boye sikoyo¶

1. Benga nimero ya urgence ya esika ofandi to déclencher ICU / Hématologie / Rheumatologie Réponse rapide ya mbala moko soki mobeli azwi thrombose simultané to dysfonctionnement aiguë ya organe na >= 2 to 3 binama na kati ya poso moko. Benga 911 na États-Unis mpe na Canada, . 999 na Royaume-Uni, . 112 na Union européenne mobimba, . 000 na Australie, to tala na buku na biso ya banimero ya mbalakaka. Kobosana te ete 46 to 50 percent ya ba maladi ya CAPS bazali na diagnostic ya liboso TE ya APS to Lupus (SLE) liboso ya kotambola na kati ya salle d’urgence.
2. Banda Pilier 1 ya Thérapie Triple CAPS Mbala moko: Héparine sans fractionnée intraveineuse thérapeutique (UFH) ( .Even in the Presence of Moderate Thrombocytopenia or Diffuse Alveolar Hemorrhage).
3. Héparine non fractionnée ezali libanga ya nse oyo esengeli mpo na kobika na CAPS (reducing mortality from > 75% to about 30% na Registre international ya CAPS) ezala na nzela ya anticoagulation médiée par antithrombine mpe inhibition directe ya ba voies ya complément classique mpe alternative.
4. Perle ya suivi ya laboratoire critique (The Lupus Anticoagulant aPTT Trap): Po mobeli azali ko circuler Lupus Anticoagulant (LA) ba anticorps e prolonger artificiellement ligne de base dépendante ya phospholipide aPTT (often to 60 to 100+ seconds yambo kutu kobanda héparine), kolandela héparine IV non fractionnée na norme aPTT ekokosa yo na sous-dose makasi ya héparine. Kolandela tango nionso IV Héparine non fractionnée na CAPS na nzela ya chromogène Anti-Factor Xa (Anti-Xa) essai (target 0.3 to 0.7 IU/mL), JAMAIS motindo aPTT. Ezali ndenge moko na .**
5. Banda Pilier 2 ya Thérapie Triple CAPS Mbala moko: Methylprednisolone Intraveineuse Pulse (500 to 1,000 mg IV Once Daily for 3 Consecutive Days, Elandi na 1 to 2 mg/kg/day IV). Kopesa ata moke te ba corticostéroïdes yo moko sans anticoagulation na CAPS, kasi pembeni ya IV Héparine mpe Plasmaphérèse, dose makasi IV Methylprednisolone ekangaka Anti-Beta-2-Glycoprotéine-I (aB2GPI) activation ya endothélial NF-kappa-B mpe Tissue Factor expression mpe en même temps ezo couvrir hémorragie surrénale bilatérale aiguë/infarctus (which complicates 13% to 26% of CAPS cases).
6. Kobanda Pilier 3 ya Thérapie Triple CAPS Na Ba Heures: Echange Thérapeutique ya Plasma ya Mokolo Na Mokolo (Plasmapheresis / TPE) MPE/TO Immunoglobuline Intraveineuse ya Dose monene (IVIG).
7. Echange thérapeutique ya plasma (TPE, Première-Line surtout tango ba Schistocytes / Anémie hémolytique microangiopathique [MAHA] to Insuffisance Rénale ezali): Echange ** .1.0 to 1.5 plasma volumes mokolo na mokolo na boumeli ya mikolo ata 3 kino 5** kosalelaka Plasma congelé ya sika (FFP) (to 50:50 FFP + 5% Albumine) mpo na ko dépouiller mécanique pathogène aB2GPI mpe aCL ba autoanticorps, ba cytokines ( .IL-1, IL-6, TNF-alpha), mpe ebakisaka biteni wana ezali kotondisa bankisi oyo ebomaka makila oyo ezali na bomoi (Antithrombin, Protein C, Protein S, and ADAMTS13).
8. Dose ya likolo IVIG (0.4 g/kg/day IV for 5 days to mpe 1.0 g/kg/day for 2 days): Kopesa soit yo moko (soki botiami ya cathéter ya aphérèse to TPE ezongisami sima) to mbala moko sima ya session moko na moko ya mokolo na mokolo ya Echange ya Plasma (never infuse IVIG right *before* a TPE session, or the apheresis machine will wash your expensive IVIG straight into the waste bag).
9. Hunt Down mpe Traite na aggressivement déclencheur précipitant ya "Second-Hit" (Infection in 49% of Cases). Kosala ba cultures ya makila ya périphérique mpe ya ligne ya STAT, ba cultures ya urine, mpe ba panneaux viraux, mpe kobanda ba antibiotiques intraveineuses ya spectre large empirique mbala moko soki ba suspecter fièvre to source infectieuse. Kotika ata moke te na mbalakaka anticoagulation liboso ya lipaso epai ya mobɛli oyo ayebani ete azali na Triple-Positive APS (always bridge closely with IV UFH or therapeutic LMWH).
10. Ko déployer Inhibition ya Complément ya Terminal (IV Eculizumab 900 mg Pɔsɔ na pɔsɔ) to Rituximab Na ebandeli ya CAPS Réfractaire to TMA Prominent (Schistocytes + Severe Thrombocytopenia + Renal Failure). Ba preuves expérimentales mpe cliniques e prouver que CAPS ya makasi etambwisami na Complexe Complément Terminal oyo ekimi ( Complexe de complément terminal) oyo ekimi (C5b-9 complexe ya attaque ya membrane) dépôt na ba cellules endothéliales (often with underlying complement regulatory gene mutations). Kopesa IV Eculizumab (Soliris) etelemisaka hémolyse intravasculaire, thrombocytopénie, mpe thrombose microvasculaire rénale na boumeli ya ngonga 48 kino 72 ntango Triple Thérapie standard ekoki te.

Nzete ya mokano: ba suspecter Syndrome Antiphospholipide Catastrophique (CAPS / Syndrome ya Asherson) mpe Thérapie Triple ya ICU¶

flowchart TD
    Patient["Mobɛli azali komonana na dysfonctionnement multi-organique progressive rapidement (>= 3 organes dans < 7 jours):<br/>- Rénale : blessure aiguë ya rein, HTN malignant, Protéinurie<br/>- Pulmonaire: ARDS / Hémorragie alvéolaire diffuse / PE<br/>- CNS: Encephalopathie, AVC, Ba crises, CVST<br/>- Cardiaque : Troponine elevée, Microthrombi myocardique<br/>- Loposo : Livedo Racemosa, Gangrène numérique, Nécrose ya loposo<br/>- Adrénal : Pasi ya flanque/libumu + Hypotension réfractaire"] --> StatWorkup["STAT Triage ya pembeni ya mbeto & ya laboratoire (Kozongisa sima TE traitement mpo na ba résultats ya anticorps):<br/>1. Frotis périphérique (Schistocytes), LDH, Haptoglobine, Plaquettes, Coags, Fibrinogène<br/>2. Benda Anti-coagulant ya Lupus (dRVVT/aPTT), Anti-Cardiolipine IgG/IgM, & Anti-Beta-2-Glycoprotéine-I IgG/IgM (LIBOSO YA Echange ya Plasma)<br/>3. Draw Random Cortisol & ACTH (Vérifier hémorragie surrénale bilatérale) + Activité ya ADAMTS13 (Bolongola TTP)"]

    StatWorkup --> TripleTherapy["LANCER EMPIRIC 'CAPS TRIPLE TÉRAPIE' MBALA MOKO NA ICU"]

    TripleTherapy --> Pillar1["PILLAR 1: Héparine infractionnée IV thérapeutique (UFH)<br/>- Monitor makasi na niveau ya ANTI-FACTEUR Xa chromogène (Cible 0,3 à 0,7 UI/mL)<br/>- JAMAIS Monitor Na aPTT Standard (Falsement prolongé par Anticoagulant Lupus)"]

    TripleTherapy --> Pillar2["PILLAR 2: Ba Corticostéroïdes IV ya Dose makasi<br/>- IV Méthylprednisolone 500 à 1.000 mg Mokolo na mokolo na boumeli ya Mikolo 3, Na sima 1 à 2 mg/kg/jour<br/>- Ezali kopekisa NF-kappa-B Storm endothélial & Ezali kosalisa Crise surrénale"]

    TripleTherapy --> Pillar3["PILLAR 3: Bosangisi ya Plasma ya monganga ya mokolo na mokolo (TPE) +/- IVIG ya dose ya likolo<br/>- Bosangisi ya ba volumes ya plasma 1,0 kino 1,5 Mokolo na mokolo x 5+ Mikolo na kosalelaka Plasma ya sika congelé (FFP)<br/>- Kotia IVIG (0,4 g/kg/jour x 5 Mikolo) NSIMA ya Session moko na moko ya TPE (Ata moke te na droite liboso ya TPE)"]

    Pillar1 --> TriggerAndRefractory{"Salisa Déclencheur ya 'Second-Hit' (Antibiotiques empiriques à spectre large soki Infection moko boye) & Tala Réponse ya 24 à 48 Heures"}
    Pillar2 --> TriggerAndRefractory
    Pillar3 --> TriggerAndRefractory

    TriggerAndRefractory -->|"Thrombocytopénie réfractaire, ba Schistocytes MAHA oyo ezali kokoba, to Insuffisance ya ba organes oyo ezali kobeba"| AddEculizumab["ESCALATE IMMEDIATELY:<br/>1. IV Eculizumab (Anti-C5 Complement Inhibitor: 900 mg IV Weekly x 4, Then 1,200 mg) [Give Meningococcal Vaccine + Ciprofloxacin/Penicillin Prophylaxis]<br/>2. IV Rituximab (375 mg/m2 Weekly x 4) to Deplete B-Cell Autoantibody Production"]

Eteni ya 1: Physiologie ya "Two-Hit" ya Syndrome ya Asherson mpe ba Critères internationales ya diagnostic¶

1. Mpo na nini ba anticorps antiphospholipides ya kimia epanzani na mbalakaka na mopepe makasi ya mikolo 7 ya ba organes ebele¶

Bato mingi batambolaka na boumeli ya bambula na ba anticorps antiphospholipides "Triple-Positifs" oyo ezali kotambola (Lupus Anticoagulant + Anti-Cardiolipin + Anti-Beta-2-Glycoprotein-I) kozanga ete makila ekóma kokangama ("The First Hit"). Mpo na nini? Pamba te na conditions normales ya repos, ba cellules endothéliales vasculaires ebombaka ba phospholipides ya membrane oyo ezali na charge négative na feuille na yango ya kati, mpe Beta-2-Glycoprotéine-I (B2GPI) ebalukaka na conformation circulaire fermée oyo ebombaka domaine na yango ya liaison antigène (Domain I).

• E déclencheur ya "Hit ya mibale" (Infection, Surgery, Trauma, Pregnancy, or Warfarin Withdrawal):
• Ntango maladi moko (Gram-negative sepsis, respiratory virus, urinary tract infection).
• Ezali ko circuler ** .B2GPI** ekangamaka na endothélium oyo ebebi mpe efungolaka na conformation ya polele "J-shaped fish crochet", ko exposer Domaine I.
• Pathogène Anti-Béta-2-Glycoprotéine-I (aB2GPI) Ba dimères IgG ba réticulation ya ba ouverts B2GPI ba molécules na ba cellules endothéliales, ba plaquettes, na ba monocytes na nzela ya Toll-Like Receptor 4 (TLR4) mpe Annexine A2, kosala ** .NF-kappa-B** mpe ** .p38 MAPK** **.
• Boucle ya amplification ya complément (C3a / C5a / C5b-9): Ba bokangami aB2GPI ba complexes immunitaires e déclenchaka activation massive ya Nzela ya Complément Classique et Alternatif, ebimisaka ba anaphylatoxines C3a mpe C5a (which recruit neutrophils to extrude prothrombotic NETs) mpe kobɛta makofi ** .C5b-9 Attaque ya membrane Ba pores complexes** na ba cellules endothéliales microvasculaires na kati ya ba reins, poumons, cerveau, motema, mpe ba glandes surrénales mobimba.

2. Critères officiels ya classification préliminaire pona APS catastrophique (Asherson et al. International Consensus) .¶

Ba cliniciens ba classer mobeli lokola oyo azali na Definite CAPS (all 4 criteria) to CAPS oyo ekoki kozala (3 of 4 criteria) oyo euti na: 1. Mibeko ya 1 ( .>= 3 Organs, Systems, or Tissues): Bilembeteli ya kliniki ya bokangami ya ** binama misato to koleka, ba systèmes, mpe/to ba tissus** (renal, pulmonary, cerebral, cardiac, cutaneous, hepatic, gastrointestinal/mesenteric, splenic, or adrenal). 2. Mibeko ya 2 ( .<= 7 Days): Bokoli ya ba manifestations cliniques na mbala moko to na moke koleka poso moko. 3. Mibeko ya 3 ( .Histopathologic Microthrombosis): Confirmation na histopathologie ya occlusion ya misisa ya mike (thrombotic microangiopathy) na enama to na tissu ata moko (typically via skin punch biopsy of livedo/necrotic lesions or renal biopsy once stabilized). 4. Mibeko ya 4 ( .Laboratory Antiphospholipid Antibodies): Présence ya Anticoagulant ya Lupus (LA), Anti-Cardiolipine ( .aCL IgG/IgM na titre ya moyenne à haute > 40 GPL/MPL to mpe > 99th percentile), mpe/to Anti-Béta-2-Glycoprotéine-I (aB2GPI IgG/IgM).

• Ntango nini ko diagnostiquer "Probable CAPS" mpe ko traité mbala moko pembeni ya mbeto: Lokola kosala biopsie ya rein na mobeli ya ICU oyo azali na maladi makasi, anticoagulé, thrombocytopénique ezali likama mpe kozela poso 12 mpo na confirmation ya anticorps mbala na mbala ezali impossible na tango ya crise aiguë, Consensus international elimboli Probable CAPS tango nionso:
• Kaka 2 organes nde ezali na kati (with Criteria 2, 3, and 4 met), OR
• Ba critères nionso 4 ekokisami sauf confirmation ya biopsie histopathologique ezangi (because the patient is too unstable/anticoagulated to biopsy), OR
• 3 organs bakozwa thrombose na boumeli ya poso 1 kino 4 atako anticoagulation.
• Mobeko ya clinique: Kosalisa CAPS oyo ekoki kozala ndenge moko na CAPS ya sikisiki na Thérapie Triple ya mobimba mbala moko.

Eteni ya 2: Diagnostic différentiel côté à côté ya ba microangiopathies thrombotiques ya ICU (CAPS vs. TTP vs. HUS/aHUS vs. HIT vs. Sepsis DIC) .¶

Ntango mobɛli ya ICU azwi baplaquettes oyo ezali kokwea nokinoki, créatinine oyo ezali komata, mobulungano ya misisa ya bɔɔngɔ, mpe anémie hémolytique na schistocytes (helmet cells) na frotis ya makila, ekesenisaka CAPS na Purpura Thrombotique Thrombocytopénique (TTP), Syndrome urémique hémolytique médié par complement (aHUS), HIT, mpe Septic DIC ezali na ntina mingi:

Eteni ya 3: Kozinda na mozindo na kati ya ba 6 organes ya mbalakaka ya CAPS (Yambo na yango Hémorragie surrénale bilatérale & hémorragie alvéolaire diffuse)¶

Ntango bazali kokamba mobɛli ya CAPS na ICU, minganga basengeli kosala ekzamɛ mpe kotambwisa na molende nyonso ba crises motoba ya binama ya signature oyo emonisaka kobika:

========================================================================
   THE 6 SIGNATURE MULTI-ORGAN THROMBOTIC CRISES OF CAPS (ASHERSON'S)
========================================================================

  1. RENAL TMA (73%):               2. PULMONARY CRISIS (60%):
     Renal interlobular/glomerular     ARDS, Pulmonary Embolism, AND
     capillary microthrombi ->         Capillaritis DIFFUSE ALVEOLAR
     Malignant HTN + Oliguric AKI.     HEMORRHAGE (DAH: Hemoptysis +
                                       Falling Hb + Ground-Glass CT).
  3. CEREBRAL / CNS (56%):             * CRITICAL PEARL: Even with DAH,
     Microvascular Encephalopathy,       continue carefully titrated IV
     Seizures, Ischemic Stroke, &        Heparin + Pulse Steroids + TPE.
     Cerebral Venous Sinus Clots.
                                    4. CARDIAC MICRO-INFARCTION (50%):
  5. CUTANEOUS ISCHEMIA (47%):         Intramyocardial microthrombi
     Branching Livedo Racemosa,        (cardiogenic shock with clean
     Splinter Hemorrhages, Digital     epicardial coronaries) + Sterile
     Cyanosis/Gangrene, Skin Ulcers.   Libman-Sacks Mitral/Aortic Valves.

  6. BILATERAL ADRENAL HEMORRHAGE / INFARCTION (13% to 26% - OFTEN MISSED.):
     * Why the Adrenal Glands? Each adrenal gland is fed by 3 arteries
       (50-60 arterioles) but drained by ONLY A SINGLE CENTRAL ADRENAL VEIN.
     * Thrombosis of that single central adrenal vein causes hemorrhagic
       venous infarction of both adrenal cortices -> Sudden Flank/Abdominal
       Pain, Hyponatremia, Hyperkalemia, & Catecholamine-Resistant Shock.
     * Lifesaving Fix: Immediate Stress-Dose IV Hydrocortisone (100 mg IV
       bolus, then 50 mg IV q6h) or Pulse IV Methylprednisolone.
========================================================================

1. Goulet d’étranglement anatomique ya misisa ya surrénale ( .Why CAPS Causes Acute Addisonian Adrenal Crisis) .¶

Pourquoi hémorragie surrénale bilatérale/infarctus ezali complication classique ya CAPS na HIT? - Glande surrénale nionso ya moto ezalaka na ba artéries ebele (superior, middle, and inferior suprarenal arteries branching into 50+ capillary plexus vessels), kasi makila nyonso ya misisa esengeli kobima na nzela ya Veine Surrénale Centrale moko, oyo ezali kaka yango moko (creating a vascular "water-hammer" bottleneck rich in platelet-activating catecholamines). - Tango microthrombi ya CAPS e occluer veine surrénale centrale moko wana bilatérale, pression veineuse na kati ya cortex surrénale emati tii tango ba glandes ekopasuka mpe ekobima makila na kati (Infarctus hémorragique lokola Waterhouse-Friderichsen). - Drapeaux rouges cliniques: Soki mobɛli oyo azali na APS/CAPS azwi pasi ya sika ya flanque bilatérale, ya mokɔngɔ, to ya epigastrique, fièvre oyo ekoki kolimbolama te, sodium ya sérum oyo ezali kokweya (hyponatremia), potassium oyo ezali komata (hyperkalemia), mpe hypothénormose oyo ekoki koboya norépinephrine, ordre mbala moko CT ya libumu (which shows enlarged, hyperdense edematous adrenal glands), benda STAT sérum aléatoire Cortisol mpe ACTH, mpe pesa mbala moko 100 mg IV Bolus ya hydrocortisone elandi na 50 mg IV nsima ya ngonga 6 nyonso (or make sure the patient is already receiving Pulse IV Methylprednisolone).

2. Paradoxe pulmonaire: Gérer hémorragie alvéolaire diffuse (DAH) Na kati ya Tempête Prothrombotique¶

Kino na 60 percent ya ba maladi ya CAPS bazuaka insuffisance respiratoire aiguë na ARDS, thromboembolisme pulmonaire, to capillaire pulmonaire non thrombotique oyo epesaka Hémorragie Alvéolaire Diffuse (DAH: hémoptyse, ba infiltrés alvéolaire bilatéraux diffus na CT ya ntolo, mpe a 1.5 to 3.0 g/dL butu mobimba kokita ya hémoglobine). - Ndenge nini maladi ya kokangama ya makila ekoki kobimisa makila na mimpululu? Na CAPS, aB2GPI ba anticorps mpe C5a e déclenchar complexe immunitaire capillaire pulmonaire (neutrophilic inflammation that necroses the alveolar capillary wall) esangani na microthrombose venulaire pulmonaire oyo ematisaka pression ya sima ya capillaire hydrostatique tii tango ba globules rouges ekosopana na ba sacs ya mopepe. - Ndenge nini ko gérer DAH na CAPS: 1. Mbala moko ematisaka immunosuppression na Pulse IV Methylprednisolone (1,000 mg/day IV x 3 days) + Echange ya Plasma Thérapeutique ya Mokolo na Mokolo (TPE) + IV Cyclophosphamide to Rituximab. 2. Equilibrer na bokebi Anticoagulation: Soki hémorragie alvéolaire ezali na likama ya bomoi mpe ba plaquettes/fibrinogène ezali critiquement moke, simbá héparine IV non fractionnée na mwa bangonga tango ozali kopesa ba Stéroïdes ya Pulse mpe Échange ya Plasma, kasi zongela dose moke/titrated IV Héparin non fractionné noki soki hémoptyse active e stabiliser, mpo kokanga héparine na boumeli ya mikolo mingi na CAPS epesaka nzela na thrombose microvasculaires ebebisa bɔɔngɔ, motema mpe rein.

Eteni ya 4: Exécution ya triple thérapie ya ICU na etape na etape & Rescue réfractaire (Eculizumab & Rituximab) .¶

1. Liste ya botali ya thérapie triple ya CAPS ya sikisiki (McMaster / EULAR / International CAPS Registry Guidelines) .¶

2. Kobikisa biologique ya ligne ya mibale mpo na CAPS oyo ekoki kozika te (Eculizumab mpe Rituximab) .¶

Soki mobɛli ya CAPS azali kokoba kokutana na ba plaquettes oyo ezali kokweya, créatinine oyo ezali komata, ba déficits neurologiques ya sika, to hémolyse microangiopathique réfractaire sima ya Heures 24 à 48 ya Thérapie Triple: 1. Blocage ya Complément ya Terminal (IV Eculizumab [Soliris] to mpe Ravulizumab [Ultomiris]): - Po na nini Esalaka: Esili 60 percent ya ba malades oyo bazali na CAPS réfractaire harbor activation grave ya complément (and many carry heterozygous mutations in complement regulatory genes like CFH, CFI, or CD46 identical to atypical HUS). Eculizumab (a humanized monoclonal antibody against complement protein C5) e bloquer clevage ya C5 na kati C5a mpe C5b-9, kokanga kobebisama ya TMA ya endothélium na kati ya 24 kino 72 heures. - Kopesa dose: 900 mg IV mbala moko na poso na boumeli ya poso 4, elandi na 1,200 mg IV na Poso ya 5 mpe sima ya poso 2 sima. - Prophylaxie méningocoque obligatoire: Po blocage C5b-9 esala susceptibilité ya Neisseria meningitidis encapsulé, kopesa quadrivalent (MenACWY) mpe Sérogroupe B ( .MenB) mangwele ya méningocoque mbala moko MPE kobanda prophylaxie antibiotique orale mokolo na mokolo (Ciprofloxacin 500 mg daily to mpe Penicillin V 500 mg twice daily) kobanda Mokolo ya 1 ya Eculizumab (do not delay Eculizumab for 2 weeks waiting for vaccine immunity). 2. B-Bosilisi ya ba cellules (IV Rituximab): - Kopesa Rituximab (375 mg/m2 IV mbala moko na poso na boumeli ya poso 4, to 1,000 mg IV na Mikolo ya 1 mpe 15) (infused after daily TPE) mpo na kosilisa yango CD20+ Ba-lymphocytes B oyo ebimisaka ba autoanticorps antiphospholipides pathogènes, mingi mingi na ba malades ya CAPS oyo bazali na thrombocytopénie makasi, hémorragie alvéolaire diffuse, to implication cardiaque/SNC.

Ba nimero ya urgence ya etuka mpe ba registres internationales ya CAPS¶

• Etats-Unis mpe Canada: Benga 911 mpo na thrombose nionso oyo bakanisaka ete ezali na ba organes ebele to na urgence ya AVC/PE. Landa Mabongisi ya Pratique clinique ya Université McMaster mpo na diagnostic mpe gestion ya Syndrome antiphospholipide catastrophique (Blood Advances) mpe Collège américain ya rhumatologie (ACR) / ASH bokambi.
• Union européenne na Royaume-Uni: Benga 112 na UE mobimba to 999 na Royaume-Uni. Bolanda Alliance européenne des associations pour la réumatologie (EULAR) Makanisi mpo na ndenge ya kosilisa maladi ya antiphospholipide epai ya mikóló (Tektonidou et al., Annals of the Rheumatic Diseases) mpe Société britannique mpo na hématologie (BSH) Mabongisi ya malako. Ba cliniciens na mokili mobimba bakoki ko consulter pe ko enregistrer ba cas na Registre international ya CAPS (ontocrf.costaisa.com/en/web/caps, oyo eyambami na Forum européen sur les anticorps antiphospholipides na Hospital Clínic na Barcelone, na Espagne, oyo etambwisami na Dr. Ricard Cervera).
• Australie na Nouvelle-Zélande: Benga 000 na Australie to 111 na Nouvelle-Zélande. Bolanda THANZ na Association ya Réumatologie ya Australie (ARA) Ba protocoles ya ICU pona Thérapie Triple na accès ya Eculizumab ya urgence.

Mituna oyo batunaka mingi¶

Ndenge nini Syndrome antiphospholipide Catastrophique (CAPS) ekeseni na Syndrome antiphospholipide ya mbala na mbala (APS)?¶

Na Syndrome antiphospholipide classique (APS), mbala mingi ba maladi bazwaka coagulation moko ya makila oyo ekabwani na misisa to ya artérie monene (lokola thrombose ya misisa ya mozindo na makolo moko, embolie pulmonaire, to AVC) to mikakatano ya zemi oyo ezongaka mbala na mbala, na fonctionnement normal na ba organes na bango mosusu. Syndrome antiphospholipide catastrophique (CAPS, to Syndrome d’Asherson) ezwamaka na nse ya 1 % ya bato ya maladi ya APS mpe esalaka lokola “mopɛpɛ thrombotique” ya mbalakaka, ya microvasculaire mobimba: na esika ya kokangama moko ya monene, ba coagulation ya makila ya mikemike na mbala moko ekangami na ba capillaires microscopiques ya binama misato to koleka oyo ezali na ntina mingi (mbala mingi ba reins, mimpululu, bɔɔngɔ, motema, loposo, mpe ba glandes surrénales) na boumeli ya mikolo 7 te, elongo na kovimba makasi ya système mpe motango ya ba plaquettes oyo ezali kokita.

Mpo na nini minganga basengeli kopesa ba traitements misato na mbala moko mpenza ("Triple Thérapie") mpo na kobikisa mobeli oyo azali na CAPS?¶

Ba données historiques oyo ewutaki na Registre international ya CAPS (oyo etali ba malades koleka 500 na mokili mobimba) e prouvé que traitement ya CAPS na ba diminateurs ya makila yango moko to na ba stéroïdes yango moko elongaki te na ba cas mingi, po CAPS ezali na ba moteurs misato oyo ezo se renforcer yango moko: (1) Fibrine kokima mpe clotting ya complément na ba petits vaisseaux, (2) Mopepe makasi ya cytokines inflammatoires na misisa ya makila bifelo, mpe (3) Ba autoanticorps antiphospholipides oyo ezali kotambolatambola mingi. "Triple Thérapie" e attaquer ba moteurs nionso misato en même temps : Héparine intraveineuse sans fractionnement etelemisaka propagation ya coagulation mpe e inhiber complément, Haute Dose IV Methylprednisolone ekanga tempête ya cytokines endothéliales, mpe Daily Therapeutic Plasma Exchange (Plasmaphérèse) mpe/to IVIG elongolaka physiquement mpe e neutraliser ba autoanticorps, kokata liwa ya bato koleka 75 % kino pene na 30 %.

Mpo na nini ba infirmiers mpe minganga bakoki te kosalela test ya makila ya aPTT standard mpo na kolandela Héparine intraveineuse na mobeli oyo azali na CAPS?¶

Bato ya maladi oyo bazali na CAPS bazalaka pene na ntango nyonso na anticorps antiphospholipide oyo ezali kotambola oyo babengaka "Lupus Anticoagulant" (LA). Na ndenge ya kokamwa, atako Anticoagulant ya Lupus esalaka ete makila ekangama makasi na kati ya nzoto ya moto, na kati ya tube ya test ya laboratoire ya verre ekangamaka na ba réactifs phospholipides oyo esalelamaka mpo na kosala test standard activé ya temps partiel ya Thromboplastin (aPTT), na ndenge ya artificiellement esalaka que aPTT ya base ya maladi ezala prolongé (na ndakisa, 85 secondes) avant ata kopesa ata goutte moko ya héparine. Soki monganga asaleli aPTT mpo na kosala titre ya goutte ya héparine, bakokanisa na libunga ete makila ya mobɛli ezali "déjà trop mince" mpe bakokitisa goutte ya héparine na niveau sub-thérapeutique ntango mobɛli azali ko coaguler tii na liwa. Na esika na yango, esengeli ntango nyonso kolandela Héparine IV na CAPS na niveau chromogène Anti-Facteur Xa (Anti-Xa) na makila (oyo etali 0,3 kino 0,7 UI/mL), oyo esimbami te na Anticoagulant ya Lupus.

Mpo na nini mbala mingi CAPS epesaka Crise Surrénale ya mbalakaka, oyo ekoki koboma moto (choc Addisonian)?¶

Mokomoko ya ba glandes surrénales na yo mibale (oyo efandaka likoló ya ba reins mpe ebimisaka cortisol mpe aldostérone oyo eumelaka bomoi) ezwa makila na nzela ya ebele ya misisa ya mikemike, kasi ebimisaka makila na yango nyonso na nzela ya Veine Surrénale Centrale moko. Na ntango ya mopepe makasi ya thrombotique CAPS, ba micro-coagulation ekangaka na pete veine surrénale wana moko oyo ezo drainer na ngambo mibale. Lokola misisa ya kobima ekangami, makila ya misisa ya makila ezongaka nsima na kati ya ba glandes surrénales nyonso mibale tii ekovimba mpe ekopasuka na kati (hémorragie surrénale bilatérale mpe infarctus). Yango elongolaka kobimisama ya cortisol na nzoto na butu mobimba, mpe epesaka mpasi makasi na flanque to na libumu, sodium moke, potassium mingi, mpe tansiɔ oyo ebomaka longola se soki basalisi yango mbala moko na ba corticostéroïdes intraveineux dose makasi (Methylprednisolone to Hydrocortisone).

Mpo na nini esengeli ata moke te kobongola bato ya maladi oyo bazali na APS Triple-Positive to CAPS ya liboso longwa na Warfarin kino na pilili ya mikolo oyo ya Anticoagulant Direct oral (DOAC) lokola Rivaroxaban to Apixaban?¶

Ba études cliniques randomisées ebele (na kati na yango ba études TRAPS na ASTRO-APS) etelemisamaki na ebandeli sima ya ko découvrir que ba malades oyo bazalaki na Syndrome Antiphospholipide "Triple-Positif" (positifs ya Lupus Anticoagulant, Anti-Cardiolipine, na Anti-Beta-2-Glycoprotéine-I) oyo bamelaki ba Anticoagulants Directs oraux (DOACs lokola rivaroxaban to apixaban) azwaki mpasi ya mbala 4 kino mbala 7 ya AVC ya misisa mpe ya kobɛla motema koleka bato ya maladi oyo bazalaki komɛla Warfarin. Ko bloquer kaka facteur ya coagulation moko (Facteur Xa to Facteur IIa) na DOAC ekoki mbala mingi te mpo na kopekisa surge massif ya thrombine mpe complément oyo etambwisami na ba anticorps antiphospholipides triple-positifs, mpe ko changer de Warfarin na DOAC ezali déclencheur documenté mpo na APS Catastrophique aigu.

Maziba mpe bokambi ya Leta¶

• Bokambami ya misala ya kliniki ya Université McMaster / ASH (Legault K et al., Avances ya makila): Bokambami ya misala ya kliniki ya McMaster RARE-Bestpractices mpo na diagnostic mpe gestion ya Syndrome antiphospholipide catastrophique (Thérapie triple: Anticoagulation, Glucocorticoïdes, mpe échange ya plasma/IVIG).
• Alliance européenne ya ba associations pona rhumatologie (EULAR, Tektonidou MG et al., Annals ya ba maladies ya rhumatisme): Makanisi ya EULAR pona gestion ya Syndrome antiphospholipide na ba adultes (Contraindication ya ba DOACs na gestion ya APS triple-Positif na CAPS).
• Maloba ya boyokani ya mokili mobimba na ntina ya ba critères ya classification mpe malako ya traitement mpo na Syndrome antiphospholipide catastrophique (Asherson RA, Cervera R, et al., Lupus / Journal of Rheumatology): Critères ya classification ya liboso mpo na CAPS défini mpe probable mpe Analyse ya ba malades 500+ oyo bawutaki na Registre international ya CAPS.
• Société britannique ya hématologie (BSH, Arachchillage DRJ et al.): Mabongisi ya bolukiluki mpe ya boyangeli ya Syndrome antiphospholipide mpe APS ya Catastrophique.
• New England Journal of Medicine (NEJM) Review (Garcia D, Erkan D): Diagnostic mpe gestion ya Syndrome antiphospholipide mpe inhibition ya complément na CAPS.

Ba guides oyo etali yango¶

• Crise surrénale mpe injection ya urgence ya maladie ya Addison
• Thrombocytopénie induite par héparine (HIT) mpe VITT: 50% ya ba plaquettes ekiti na Mokolo ya 5 kino 10 mpe Argatroban
• Ba crises ya éclampsie, syndrome ya HELLP, prééclampsie sima ya kobota, mpe triage ya magnésium
• Sepsis mpe choc septique
• Mituya ya mbalakaka na kotalela mboka